IP Library Granted Patent US 9,616,136
Granted Patent B2
US 9,616,136 · App. 14/951,105 · Granted Apr 11, 2017

N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,616,136
App. No.
14/951,105
Granted
Apr 11, 2017
Kind
B2
Abstract

The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.

Claims (27)

1. A method comprising administering to a mammal a compound having the following structure:

wherein:

Ar is aryl, optionally substituted with halo;

R 1 is lower alkyl;

the dotted line (“---”) represents a covalent bond;

X 1 is a spacer moiety; and

POLY 1 is a poly(alkylene oxide),

and pharmaceutically acceptable salts thereof.

2. The method of claim 1 , wherein the compound is encompassed within the formula:

wherein:

Ar is aryl, optionally substituted with halo;

R 1 is lower alkyl;

X 1 is a spacer moiety; and

POLY 1 is a poly(alkylene oxide),

and pharmaceutically acceptable salts thereof.

3. The method of claim 1 , wherein the compound is encompassed within the formula:

wherein:

Ar is aryl, optionally substituted with halo;

R 1 is lower alkyl;

X 1 is a spacer moiety; and

POLY 1 is a poly(alkylene oxide),

and pharmaceutically acceptable salts thereof.

4. The method of claim 1 , wherein the poly(alkylene oxide) is a poly(ethylene oxide).

5. The method of any one of claims 1 , 3 and 4 , wherein the poly(alkylene oxide) has from about 2 to about 30 monomers.

6. The method of claim 5 , wherein the poly(alkylene oxide) has from about 2 to about 10 monomers.

7. The method of claim 1 , wherein the poly(alkylene oxide) includes an alkoxy or hydroxy end-capping moiety.

8. A method comprising administering to a mammal a compound selected from the group consisting of (2R) N-benzyl-2-carboxy mPEG 1 amino-3-methoxy propionamide, (2R) N-benzyl-2-carboxy mPEG 2 amino-3-methoxy propionamide, (2R) N-benzyl-2-carboxy mPEG 3 amino-3-methoxy propionamide, (2R) N-benzyl-2-carboxy mPEG 4 amino-3-methoxy propionamide, (2R) N-benzyl-2-carboxy mPEG 5 amino-3-methoxy propionamide, (2R) N-benzyl-2-carboxy mPEG 6 amino-3-methoxy propionamide, (2R) N-benzyl-2-carboxy mPEG 7 amino-3-methoxy propionamide, (2R) N-benzyl-2-carboxy mPEG 8 amino-3-methoxy propionamide, (2R) N-benzyl-2-carboxy mPEG 9 amino-3-methoxy propionamide, and pharmaceutically acceptable salts of each of the foregoing.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Apr 17, 2020
From: TC LENDING, LLC, AS COLLATERAL AGENT
To: NEKTAR THERAPEUTICS
Reel/Frame 053180/0009 →
SECURITY INTEREST Recorded Mar 15, 2016
From: NEKTAR THERAPEUTICS
To: TC LENDING, LLC, AS A COLLATERAL AGENT
Reel/Frame 037990/0511 →